Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: AUManufacturing
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million
  • Under the plan, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are priced at 65 cents
  • This price represents a 17.3 per cent discount to the five-day volume-weighted average price
  • LGP will use the money to speed-up sales and marketing efforts in both Australia and overseas as well as expand its manufacturing capacity
  • Shares in Little Green Pharma have dropped 8.75 per cent and are trading at 73 cents each

Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million.

This follows on from a recently announced placement to sophisticated, experienced and professional investors to raise $22 million.

All up, around 34 million shares were issued to participants at 65 cents.

Under the SPP, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are also priced at 65 cents.

This price represents a 17.3 per cent discount to the five-day volume-weighted average price.

The company’s Australian-based Directors, Angus Caithness and Neale Fong, intend to apply for the maximum $30,000 worth.

In the event of oversubscriptions, LGP has the right to scale-back applications.

LGP will use the money from both the placement and share purchase plan to speed-up sales and marketing efforts in both Australian and overseas markets, and expand its manufacturing and cultivation capacity.

The plan is set to close on March 3 and shares will be issued on March 11 and begin trading on the ASX on March 12.

Shares in Little Green Pharma have dropped 8.75 per cent and are trading at 73 cents each at 1:56 pm AEDT.

LGP by the numbers
More From The Market Online

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…

Little Green Pharma closely eyeing USA’s legal downgrade of Cannabis danger

Overnight, the Biden government did something sure to give their counterparts a stir – the USA…

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…